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IMPORTANCE Sepsis-associated acute kidney injury (AKI) adversely affects long-term kidney
outcomes and survival. Administration of the detoxifying enzyme alkaline phosphatase may
improve kidney function and survival.
OBJECTIVE To determine the optimal therapeutic dose, effect on kidney function, and
adverse effects of a human recombinant alkaline phosphatase in patients who are critically ill
with sepsis-associated AKI.
DESIGN, SETTING, AND PARTICIPANTS The STOP-AKI trial was an international (53 recruiting
sites), randomized, double-blind, placebo-controlled, dose-finding, adaptive phase 2a/2b
study in 301 adult patients admitted to the intensive care unit with a diagnosis of sepsis and
AKI. Patients were enrolled between December 2014 andMay 2017, and follow-up was
conducted for 90 days. The final date of follow-up was August 14, 2017.
INTERVENTIONS In the intention-to-treat analysis, in part 1 of the trial, patients were
randomized to receive recombinant alkaline phosphatase in a dosage of 0.4mg/kg (n = 31),
0.8mg/kg (n = 32), or 1.6mg/kg (n = 29) or placebo (n = 30), once daily for 3 days, to establish
the optimal dose. The optimal dosewas identified as 1.6mg/kg based onmodeling approaches
and adverse events. In part 2, 1.6mg/kg (n = 82)was comparedwith placebo (n = 86).
MAIN OUTCOMES ANDMEASURES The primary end point was the time-corrected area under
the curve of the endogenous creatinine clearance for days 1 through 7, divided by 7 to provide
amean daily creatinine clearance (AUC1-7 ECC). Incidence of fatal and nonfatal (serious)
adverse events ([S]AEs) was also determined.
RESULTS Overall, 301 patients were enrolled (men, 70.7%; median age, 67 years
[interquartile range {IQR}, 59-73]). From day 1 to day 7, median ECC increased from 26.0
mL/min (IQR, 8.8 to 59.5) to 65.4mL/min (IQR, 26.7 to 115.4) in the recombinant alkaline
phosphatase 1.6-mg/kg group vs from 35.9mL/min (IQR, 12.2 to 82.9) to 61.9 mL/min (IQR,
22.7 to 115.2) in the placebo group (absolute difference, 9.5 mL/min [95% CI, −23.9 to 25.5];
P = .47). Fatal adverse events occurred in 26.3% of patients in the 0.4-mg/kg recombinant
alkaline phosphatase group; 17.1% in the 0.8-mg/kg group, 17.4% in the 1.6-mg/kg group, and
29.5% in the placebo group. Rates of nonfatal SAEs were 21.0% for the 0.4-mg/kg
recombinant alkaline phosphatase group, 14.3% for the 0.8-mg/kg group, 25.7% for the
1.6-mg/kg group, and 20.5% for the placebo group.
CONCLUSIONS AND RELEVANCE Among patients whowere critically ill with sepsis-associated
acute kidney injury, human recombinant alkaline phosphatase compared with placebo did not
significantly improve short-term kidney function. Further research is necessary to assess
other clinical outcomes.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02182440
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A cute kidney injury (AKI) occurs in up to 60% of pa-tients in intensive care units (ICUs), and its incidenceis increasing.1,2 Development of AKI in patients with
sepsis is associated with increased mortality,3 and survivors
are at risk of developing chronic kidney disease,4 resulting in
a burden for both patient and society. Sepsis-associated AKI
is a multifactorial syndrome with inflammatory, nephro-
toxic,and ischemic insultsoccurringsimultaneouslywithother
pathophysiological responses rapidly leading to kidney
impairment.5 Currently, no pharmacologic interventions are
available to prevent or treat AKI.6
Alkaline phosphatase is an endogenous enzyme that
exerts detoxifying effects through dephosphorylation of
various compounds, including bacterial endotoxins7 and
proinflammatory mediators such as extracellular adenosine
triphosphate.8 In animal sepsis models, treatment with
alkaline phosphatase attenuated systemic inflammation
and organ dysfunction and improved survival rates.9 In 2
small clinical trials, administration of bovine alkaline phos-
phatase significantly improved kidney function in patients
with sepsis.10,11
Based on these results, a human recombinant form of
alkaline phosphatase was developed that combined the
properties of 2 human isoenzymes, intestinal and placental
alkaline phosphatase.12 Replacing the crown domain of
intestinal alkaline phosphatase (the most biologically active
isoenzyme) with the crown domain of placental alkaline
phosphatase (which has the longest half-life) created a
highly stable, biologically active enzyme.12 The therapeutic
effects of human recombinant alkaline phosphatase were
confirmed in various AKI models. In human proximal tubu-
lar epithelial cells, recombinant alkaline phosphatase was
able to dephosphorylate endotoxin and adenosine triphos-
phate, resulting in an attenuated inflammatory response.13
In rats, renal ischemia–induced and inflammation-induced
AKI was attenuated by recombinant alkaline phosphatase.14
The intent of the current clinical trial was to determine the
optimal therapeutic dose, effect on kidney function, and
adverse effects of recombinant alkaline phosphatase in
patients with sepsis-associated AKI.
Methods
Trial Design and Participants
The study protocol and informed consent form were
reviewed and approved by the institutional review board or
independent ethics committee at each participating site.
The trial was conducted in accordance with ethical prin-
ciples of Good Clinical Practice. Prior to initiation of any
study-related procedures, written informed consent was
obtained from the patient or the patient’s legal representa-
tive. Race and ethnicity information was self-reported or
from a first-degree relative in accordance with the US Food
and Drug Administration guidance. Data were obtained
from all sites, except those from France, where it is prohib-
ited to collect data on race/ethnicity. The reason for inclu-
sion of race/ethnicity in this study was that this was the first
inpatient trial with recombinant alkaline phosphatase and
therefore differences in, for example, pharmacokinetics
could be possible.
The STOP-AKI trial was an international randomized,
double-blind, placebo-controlled, 4 parallel-group, dose-
finding, adaptive phase 2a/2b trial conducted in critically ill
adults with sepsis-associated AKI. The protocol, including
slight changes in eligibility criteria (upper age limit from 80
years to 85 years, weight limit from ≤100 kg to ≤115 kg, sepsis
time window from <72 hours to <96 hours, and the time
window in which the serum creatinine increase should be
observed from <24 hours to <48 hours) implemented after
inclusion of 120 patients, was published previously15
(Supplement 1 and Supplement 2). Patients admitted to the
ICU who were aged 18 to 85 years with a diagnosis of
sepsis,16 a diagnosis of AKI,17 and were not expected to have
a rapidly fatal outcome were eligible for study participation
(for an overview of all inclusion and exclusion criteria, see
eMethods 1 in Supplement 3). Prior to the administration of
the study drug, to ensure that patients with prerenal AKI
were not enrolled, the AKI diagnosis needed to be recon-
firmed. In practice, patients were volume resuscitated and
only when AKI demonstrated to be nonresolving (as defined
by a sustained increase in serum creatinine corrected
for fluid resuscitation or ongoing oliguria), the patient
remained eligible.
Patientsenrolledduring the firstpartof thestudywere ran-
domly assigned to receive either placebo or 1 of 3 recombi-
nant alkaline phosphatase doses (0.4, 0.8, or 1.6mg/kg) once
daily for 3 days using a 1:1:1:1 allocation ratio.
The data and safety monitoring board (DSMB) performed
regular, unblinded safety evaluations. After the inclusion of
120 patients, futility or superiority of the intervention on the
primary end point data and the fit to an assumed maximum
effect attributable to the drug (Emax) model dose-response
curve was assessed (eMethods 2 in Supplement 3). The adap-
tive design directed the cessation of 2 treatment groups at
the interim analysis, as described in the statistical analysis
plan. The DSMB was provided with the time-corrected
(ie, measured per day) AUC of the endogenous creatinine
Key Points
Question Does the use of human recombinant alkaline
phosphatase improve kidney function in patients who are critically
ill with sepsis-associated acute kidney injury?
Findings In this randomized, double-blind, placebo-controlled,
dose-finding adaptive phase 2a/2b trial enrolling 301 adults,
the optimal therapeutic dose of recombinant alkaline phosphatase
was 1.6 mg/kg. Treatment with this dose for 3 days when
added to standard care resulted in a median increase in
endogenous creatinine clearance of 27.6mL/min vs 14.7 mL/min
for placebo in the first 7 days, a difference that was not
statistically significant.
Meaning Among patients who were critically ill with
sepsis-associated acute kidney injury, treatment with human
recombinant alkaline phosphatase did not improve kidney
function in the first week of treatment.
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clearance for days 1 through 7, divided by 7 to provide amean
daily creatinine clearance (AUC1-7 ECC) (primary end point)
and safety data of the patients in part 1 of the study. The
DSMB was instructed to select the highest dose, provided
that the Emax model applied and that no safety concerns pro-
hibited the selection of this dose. This dose selection method
was based on the observation that biologics exhibit a linear or
Emax dose response correlation.18 Patients were randomized
to either placebo or the selected dose of recombinant alkaline
phosphatase in part 2.
Trial Oversight
All study medication was manufactured by Nova Laborato-
ries (Leicester, UK) according to Good Manufacturing Prac-
tice regulations. The design of the study was discussed with
European and US regulatory agencies. Following the interim
analysis, an adjudication committee was installed as advised
by the DSMB and steering committee to adjudicate the day 1
to 7 ECC data of all patients (eMethods 3 in Supplement 3).
Randomization and StudyMedication
The randomization schedule was stratified by site. An inde-
pendent statistician generated a permuted block randomiza-
tion schedule (per 8 in part 1 and per 4 in part 2) for an inter-
active voice/web response system, which linked sequential
patient randomization numbers to treatment codes. Study
drug dose rationale15 is explained in eMethods 4 in Supple-
ment 3. The lowest dose was chosen with predicted trough
plasma concentrations below the assumed effective concen-
tration. The middle and high doses were chosen based on
trough concentrations reaching or exceeding, respectively,
the estimated effective concentration. Study drug was
administered as a 1-hour intravenous infusion within 24
hours after sepsis-associated AKI was first diagnosed, and
then 24 hours (±1 hour) and 48 hours (±1 hour) following
administration of the first dose. Administration of nephro-
toxic drugs was avoided where possible, as recommended by
Kidney Disease: Improving Global Outcomes (KDIGO)
guidelines.19 Personnel involved in this study were blinded to
treatment assignment. To maintain the blinding, clinicians
were not allowed to measure circulating alkaline phospha-
tase concentrations until day 14 (details on blinding in
eMethods 5 in Supplement 3).
OutcomeMeasures
Primary End Point
The primary objective of this study was to determine the
optimal therapeutic dose and adverse effects (AEs) of recom-
binant alkaline phosphatase, and to evaluate its effect on
kidney function (AUC1–7 ECC). In view of the limitations of
serum creatinine values in patients who are not in a steady
state and the limited feasibility to use other measures of
kidney function, ECC was chosen as the primary efficacy end
point.20 All patients had an indwelling catheter to ensure
accurate measurements of urine volume, with a urine collec-
tion period of 6 hours (±1 hour) daily.21,22 In patients who
were anuric, an ECC of 0 mL/min was imputed. The mean
value of the serum creatinine concentration measured at the
beginning and at the end of the urine collection period was
used for ECC calculations.15
Key Secondary End Point
Requirement for renal replacement therapy (RRT) was the
main related clinical parameter. Sites were advised to follow
criteria for the initiation and termination of RRT.23 Only
continuous forms of RRTwere allowed during the first 7 days
following enrollment to prevent a rebound effect on ECC by
intermittent hemodialysis.
Secondary End Points
Kidney secondary endpoints includedECCandbloodureani-
trogen clearanceup throughday28, urinevolume, serumcre-
atinine, blood urea nitrogen, proteinuria, and estimated glo-
merular filtration rate.Nonkidney secondary endpointswere
liver function, pulmonary function, shock-free days, Sequen-
tial Organ Failure Assessment (SOFA) scores, biomarker as-
sessment, andmortality. Apriori exploratory subgroupanaly-
seswere planned todeterminewhether recombinant alkaline
phosphatase treatment demonstrates different levels of effi-
cacy in specific patient groups.
Other End Points
Other exploratory end points included composite major
adverse kidney events (MAKE) scores at days 28, 60, and 90;
serology; ICU and hospital length of stay; and quality of life.
All end points are specified in eMethods 6 in Supplement 3.
Adverse Events
Incidence of fatal and nonfatal (serious) AEs ([S]AEs), toler-
ability, pharmacokinetics (in the first 120 patients), immuno-
genicity, laboratory assessments, vital signs, and electrocar-
diography data were included in the safety analysis.
Statistical Analyses
Custom-programmed simulations were performed using
SAS software (SAS Institute), version 9.2, to determine power
and type I error rate of the chosen sample size and design
in a number of different dose-response scenarios. Each sce-
nario assumed a standard deviation of 49 mL/min for the pri-
mary end point with an assumed response of 60 mL/min for
the placebo group, and from 60mL/min (no treatment effect)
to 79 mL/min (strong treatment effect) for the recombinant
alkaline phosphatase dose groups. These estimations and
standard deviation were taken from the previous trial using
bovine alkaline phosphatase.11 A sample size was planned
of 30 patients per treatment group in part 1 with an addi-
tional 85 patients recruited to the optimal recombinant
alkaline phosphatase dose and placebo treatment groups in
part 2, (eMethods 7 in Supplement 3). Missing values were
imputed by interpolation between measured values and
extrapolation based on last observation carried forward,
according to predefined rules described in the statistical
analysis plan. The safety data set consisted of all patients
who were assigned to a treatment group and received at least
1 dose of study drug. Efficacy and exploratory end points
were analyzed according to the intention-to-treat (ITT)
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principle for patients from whom informed consent was
obtained and who were randomized to a treatment group.
Patientswhowere randomizedduring interimanalysis and
who were assigned to 1 of the 2 treatment groups that were
dropped following interim analysis were not part of the ITT
population. The per-protocol analysis supplemented the ITT
analysis and compared the intervention groups with the pla-
cebo group for patients who received study medication ac-
cording to the study protocol andhadnomore than 2missing
ECC values on days 1 through 7, as detailed in the statistical
analysis plan.
For the descriptive statistics, continuous variables are
presented as least-square means with standard error of
mean, or median with interquartile range, depending on
their distribution. Normally distributed variables were
compared using the t test; Mann-Whitney U tests were used
to compare nonnormally distributed variables. Categorical
(and binary) variables are presented as numbers with per-
centages and analyzed using χ2 tests. Survival analyses with
Kaplan-Meier curves were used for graphical presentation.
Cox proportional hazard regression analyses were used to
estimate the hazard ratio for survival and for the number
of RRT-free, shock-free, and mechanical ventilation–free
days during study days 1 through 28 with the use of recom-
binant alkaline phosphatase vs placebo. The assumption of
proportional hazards was confirmed by visual inspection
of those curves.
A hierarchical method was employed to address any
multiplicity arising from the analysis of the key secondary
end point. In case of a nonsignificant effect on the primary
outcome measure, RRT requirement is viewed as an explor-
atory end point. All analyses performed on the other sec-
ondary end points were for exploratory purposes only;
therefore, no further multiplicity adjustment was used. The
analysis of the primary efficacy end point was performed
by analysis of variance with site as a fixed effect.
Figure 1. Flow of Patients Through the STOP-AKI Trial of Recombinant Alkaline Phosphatase in Acute Kidney Injury (AKI)
326 Patients assessed for eligibility
25 Excluded
11 Did not meet AKI criteria
1 Required immunosuppressant therapy
9 Other exclusion criteria (not specified)
3 Did not meet time window
1 Required RRT in <24 h
301 Randomized
116 Continued in the ITT analysis
(part 2)
Day 60
116 Completed follow-up
111 Continued in the ITT analysis
(part 2)
Day 60
109 Completed follow-up
30 Included in the ITT analysis
(part 1)b
86 Included in the ITT analysis
(part 2)
112 Included in the safety analysis
2 Did not receive placebo within
the set time frame
1 Died prior to placebo
administration
1 Withdrew consent prior to
placebo administration
29 Included in the ITT analysis
(part 1)b
82 Included in the ITT analysis
(part 2)
109 Included in the safety analysis
1 Withdrew consent prior to
study drug administration
1 Kidney function improved
considerably prior to study
drug administration
32 Included in the ITT analysis
35 Included in the safety analysis
3 Excluded due to randomization
during interim analysisa
31 Included in the ITT analysis
38 Included in the safety analysis
1 Died prior to study drug
administration
8 Excluded due to randomization
during interim analysisa
116 Randomized to receive placebo111 Randomized to receive
1.6 mg/kg of recombinant
alkaline phosphatase
39 Randomized to receive
0.4 mg/kg of recombinant
alkaline phosphatase
35 Randomized to receive
0.8 mg/kg of recombinant
alkaline phosphatase
2 Lost to follow-up
Day 90
115 Completed follow-up
Day 90
107 Completed follow-up
1 Lost to follow-up2 Lost to follow-up
AKI indicates acute kidney injury; ITT, intention-to-treat; RRT, renal replacement
therapy; and STOP-AKI, Safety, Tolerability, Efficacy, and Quality of Life Study of
Human Recombinant Alkaline Phosphatase in the Treatment of Patients With
Sepsis-Associated Acute Kidney Infection. Part 1 of the trial identified the
optimal dose of recombinant alkaline phosphatase. Part 2 compared the
optimal dose (1.6 mg/kg) with placebo.
a The ITT population included patients fromwhom informed consent was
obtained and whowere randomized to a treatment group. The ITT population
did not include patients who were randomized during interim analysis and
whowere assigned to the human recombinant alkaline phosphatase
0.4mg/kg or 0.8mg/kg treatment group because these 2 treatment groups
were dropped following interim analysis.
bAn unblinded interim analysis was conducted on the part 1 data to determine
the optimal recombinant alkaline phosphatase dose for part 2. This analysis
compared the primary efficacy end point and a selection of the safety
data for the 4 treatment groups from part 1. The interim analysis was
conducted when the first 7 days of laboratory data had been collected
for 120 patients from part 1.
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Table 1. Demographic and Baseline Disease Characteristics of PatientsWhoWere Critically Ill With Sepsis-Associated Acute Kidney Injury
TreatedWith Recombinant Alkaline Phosphatase vs Placebo, Intention-to-Treat Population
Characteristics
Recombinant Alkaline Phosphatase Groups, No. (%)
Placebo Group (n = 116),
No. (%)0.4 mg/kg (n = 31) 0.8 mg/kg (n = 32) 1.6 mg/kg (n = 111)
Age, median (IQR), y 67.0 (61.0-72.0) 66.5 (62.5-72.0) 65.0 (57.0-73.0) 68.0 (61.0-75.0)
Men 23 (74.2) 16 (50.0) 82 (73.9) 84 (72.4)
Women 8 (25.8) 16 (50.0) 29 (26.1) 32 (27.6)
Race/ethnicity
White 25 (80.6) 27 (84.4) 95 (85.6) 95 (81.9)
Black 0 0 1 (0.9) 4 (3.4)
Asian 2 (6.5) 0 1 (0.9) 1 (0.9)
Other (specifics not obtained) 0 1 (3.1) 0 0
Not collected 4 (12.9) 4 (12.5) 14 (12.6) 16 (13.8)
Weight, median (IQR), kg 78.0 (70.0-86.0) 79.0 (72.0-90.0) 80.0 (71.8-90.0) 79.2 (70.0-86.5)
Height, median (IQR), cm 172.5 (165.0-184.0) [n=30] 167.0 (160.0-174.0) [n=29] 173.0 (168.0-179.0) [n=110] 174.0 (165.0-178.0) [n=115]
BMI, median (IQR) 25.8 (22.4-28.4) [n=30] 27.4 (25.2 -30.7) [n=29] 26.8 (23.9 -30.2) [n=110] 26.3 (23.9-29.4) [n=115]
Disease severity, median (IQR)
APACHE II scorea 30.0 (25.0-35.0) 26.0 (20.0-34.5) 25.0 (19.0-31.0) [n=110] 26.0 (20.0-33.5)
SAPS IIb 52.0 (42.0-70.0) [n=30] 50.5 (38.0-60.5) 50.0 (42.0-61.0) [n=97] 47.0 (39.0-60.0) [n=97]
SOFA scorec 10.0 (8.0-13.0) [n=29] 9.0 (8.0-11.0) 10.0 (8.0-12.0) [n=108] 10.0 (8.0-12.0) [n=113]
Mechanical ventilation 23 (74.2) 20 (62.5) 70 (63.1) 68 (58.6)
Vasopressor/inotropic
therapy use
28 (90.3) 30 (93.8) 102 (91.9) 103 (88.8)
Vital signs
Heart rate, median (IQR),
beats/min
93.0 (77.0-115.0) [n=31] 90.0 (75.5-107.5) 95.0 (83.0-110.0) 98.0 (85.0-111.0)
Systolic BP, median (IQR),
mm Hg
108.0 (100.0-119.0) 118.5 (96.0-131.0) 107.0 (95.0-119.0) 112.0 (101.5-131.5)
Diastolic BP, median (IQR),
mm Hg
54.0 (49.0-62.0) 58.0 (54.0-62.0) 55.0 (49.0-62.0) [n=110] 56.5 (51.0-63.5)
Body temperature 31 (100) 32 (100) 108 (100) 114 (100)
<36°C 4 (12.9) 5 (15.6) 11 (9.9) 11 (9.5)
≥36°C-≤38°C 20 (64.5) 22 (68.8) 79 (71.2) 76 (65.5)
>38°C 7 (22.6) 5 (15.6) 18 (16.2) 27 (23.3)
Kidney function
eGFR, median (IQR), mL/mind 27.2 (20.0-42.4) [n=27] 25.6 (20.4-40.7) [n=28] 29.7 (20.5-46.5) [n=98] 37.5 (23.9 -50.8) [n=102]
ECC, median (IQR), mL/mine
Day 0 14.4 (8.8-58.0) [n=10] 26.0 (5.4-30.6) [n=12] 24.1 (10.5-54.9) [n=46] 31.8 (14.7-62.5) [n=49]
Day 1 28.3 (4.3-64.4) [n=30] 25.2 (9.4 -61.0) [n=31] 26.0 (8.8-59.5) [n=102] 35.9 (12.2-82.9) [n=103]
AKI stagef 31 (100) 32 (100) 109 (100) 112 (100)
1 (Least affected) 22 (71.0) 23 (71.9) 81 (73.0) 91 (78.4)
2 5 (16.1) 5 (15.6) 17 (15.3) 16 (13.8)
3 (Most affected) 4 (12.9) 4 (12.5) 11 (9.9) 5 (4.3)
Urine output, median (IQR),
mL/h
50.0 (21.7-101.7) [n=13] 27.4 (16.4-50.0) [n=14] 39.1 (10.9-85.7) [n=50] 60.0 (21.8-99.3) [n=53]
Serum creatinine,
median (IQR), mg/dL
2.3 (1.5-2.8) [n=29] 1.9 (1.5-2.8) 2.0 (1.4-2.8) [n=110] 1.8 (1.3-2.4) [n=113]
Abbreviations: AKI, acute kidney injury; APACHE II, Acute Physiology and
Chronic Health Evaluation II; BMI, bodymass index—weight in kilograms divided
by height in meters squared; BP, blood pressure; ECC, endogenous creatinine
clearance; eGFR, estimated glomerular filtration rate; SAPS II, Simplified Acute
Physiology Score II; SOFA, Sequential Organ Failure Assessment.
SI conversion factors: To convert ECC tomL/s, multiply by 0.0167.
a APACHE II scores range from0-71, with higher scores indicating greater
severity. For example, a patient with APACHE II score of 26 at admission,
onmechanical ventilation and vasopressor support, could be elderly
(eg, 76 y [6 points]), with a temperature of 39.5°C (3 points), mean arterial
pressure 62mmHg (2 points), heart rate 145/min (3 points), respiratory rate
37/min (3 points), PaO2 65mmHg (1 point), arterial pH 7.25 (2 points),
serumNa+ 152mEq/L (1 point), creatinine 140mg/dL (2 points), hematocrit
47% (1 point), and white blood cell count 29 ×109/L (2 points).
b SAPS II ranges from0-163, with higher scores indicating greater severity.
c SOFA scores range from0-24, with higher scores indicating more severe
dysfunction. Themaximal deviation from normal in 24 h at baseline was used
for heart rate, blood pressure, body temperature, and AKI stage.
d The eGFRwas calculated according to the Chronic Kidney Disease
Epidemiology Collaboration equation.24
e Study drug infusion was administrated as soon as possible, and investigators
did not wait until data of day 0were completed. Therefore, data are given as
change from day 1, the day of study drug infusion.
f AKI stage was stratified according to the AKI-Network definition.25
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Four post hoc analyses were performed: First, on the pri-
mary end point, a sensitivity analysis using a mixed-effects
modelwith randomterms for sitewasperformed.Second, sen-
sitivity analyses were undertaken using amixedmodel of re-
peatedmeasures (MMRM)with timeofmeasurementasa fixed
effect and site and patient (nested within site) as random ef-
fects. This analysis was initially undertaken on data with im-
putation to align with the prespecified analysis of the pri-
mary end point and additionally without imputation for the
data from day 1 through day 28. Third, to determine to what
extent kidney function influences its recovery, baseline cre-
atinine clearance was correlated with the primary end point
AUC1-7 ECC. Fourth, a post hoc, forward stepwise, multivari-
able analysis was undertaken to assesswhether the observed
differences in overall survival were related to baseline imbal-
ances in prognostic factors. The following factors were con-
sidered; timeto treatment,C-reactiveprotein, sex,weight, age,
AcuteKidney InjuryNetwork stage, PaO2/FiO2 ratio,mechani-
cal ventilation status, vasopressor and inotropic therapy,
Kidney Injury Molecule-1, ECC, Simplified Acute Physiology
Score II (SAPS II), SOFA score, and Acute Physiologic Assess-
ment and Chronic Health Evaluation II (APACHE II) score.
Proportional hazards were assumed.
Because thesewere exploratory analyses,model assump-
tionswere not assessed in any formalway except by confirm-
ingaconsistenteffect insubgroupsas indicatedbyForestplots.
A Cox proportional hazards model including treatment was
fitted to the data togetherwith each of the prognostic factors.
Theprognostic factorhaving the lowestPvalueonoverall sur-
vival was chosen to be in the model. A model containing this
factor, treatment, and each of the remaining factorswas then
fitted to the data and the second most influential factor was
chosen based on the lowest P value. This process was contin-
ueduntil the introductionofanynewfactordidnotaffectover-
all survival significantly (P > .10).
All statistical tests performed on the ITT populationwere
conducted with SAS (SAS Institute), version 9.4, and with a
2-sided P value less than .05 for significance.
Results
Participants
From December 2014 through May 2017, of 326 patients who
passedan initial screen, 301patients (men, 70.7%;medianage,
67years[interquartilerange{IQR},59to73])wereenrolledacross
53 sites in 11 countries in theEuropeanUnionandUnitedStates
(eTable 1 in Supplement 3). Siteswere active for 17months (±8
months).Follow-upwasconductedfor90daysandthefinalvisit
took place on August 14, 2017. The safety analysis included
294patients and ITT included290patients. In the ITTdata set,
patients received recombinant alkaline phosphatase doses of
0.4mg/kg (n = 31),0.8mg/kg (n = 32), 1.6mg/kg (n = 29 inpart
1 andn = 82 in part 2), or placebo (n = 30 in part 1 andn = 86 in
part2)(Figure1).Randomizationresultedinwell-balanceddemo-
graphicandpatientcharacteristics (Table 1; forexploratorysub-
group analyses, see eFigures 1-23 in Supplement 3.
Primary End Point
In part 1, the dose-finding part of the trial, themedian AUC1–7
ECC was 47.0 mL/min (IQR, 6.6 to 88.4) in the 0.4-mg/kg re-
combinant alkalinephosphatase group, 63.5mL/min (IQR, 8.1
Figure 2. Endogenous Creatinine Clearance (ECC) Among PatientsWhoWere Critically Ill With Sepsis-Associated Acute Kidney Infection
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AUC1-7 ECC indicates the area under the time-corrected (ie, measured per day)
curve (AUC) for ECC from day 1 through 7, divided by 7 to provide amean daily
creatinine clearance. A, Median increase in ECC from baseline to day 28 from
part 1 and part 2 (combined data) of the trial. Error bars indicate distribution
free intervals. The data points of the 2 treatment groups were slightly staggered
to avoid superimposition. B, Median AUC1-7 ECC for part 1 and part 2 (combined
data) of the trial. The top and bottom of the boxes indicate the IQR, whiskers
indicate 95% CI, and the circles indicate the individuals whose values were
outside the 5th and 95th percentiles of the AUC1–7 ECC.
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to 96.8) in the 0.8-mg/kg recombinant alkaline phosphatase
group, and 60.7 mL/min (IQR, 3.7 to 92.4) in the 1.6-mg/kg
recombinant alkaline phosphatase group compared with
46.2 mL/min (IQR, 21.5 to 114.6) in the placebo group.
Following the interim analysis, the DSMB advised con-
tinuing thestudywith 1.6mg/kgof recombinantalkalinephos-
phatase. As per the statistical analysis plan, only the effects
of the 1.6-mg/kg recombinantalkalinephosphatasegroupwere
comparedwith those of the placebo group in the primary end
point analysis. Fromday 1 today7,medianECC increased from
26.0 mL/min (IQR, 8.8 to 59.5) to 65.4 mL/min (IQR, 26.7 to
115.4) in the1.6-mg/kgrecombinantalkalinephosphatasegroup
vs from 35.9 mL/min (IQR, 12.2 to 82.9) to 61.9 mL/min (IQR,
22.7 to 115.2) in the placebo group, resulting in an AUC1–7 ECC
of 55.1 mL/min (IQR, 15.0 to 93.9) in the 1.6-mg/kg recombi-
nant alkaline phosphatase group vs 45.6mL/min (IQR, 17.7 to
112.4) in the placebo group (absolute difference, 9.5 mL/min
[bootstrap 95% CI, −23.9 to 25.5]; P = .47) (Figure 2). For the
primary end point, 10.2% of data weremissing and following
the judgmentof theadjudicationcommittee, 3.1%ofdatawere
discarded. Missing or discarded data were imputed accord-
ing to the prespecified method.
Secondary End Points
TherequirementofRRT(days 1-28)was36.0%in the 1.6-mg/kg
recombinant alkaline phosphatase group vs 29.3% in the
Table 2. Adverse Events and Serious Adverse Events in the First 28 Days Among PatientsWhoWere Critically Ill With Sepsis-Associated
Acute Kidney Injury TreatedWith Recombinant Alkaline Phosphatase vs Placebo, in the Safety Data Populationa
Adverse Event
Adverse Events From Day 1-28, No. (%) Serious Adverse Events From Day 1-28, No. (%)
Recombinant Alkaline Phosphatase Groups Placebo
Group
(n = 112)
Recombinant Alkaline Phosphatase Groups Placebo
Group
(n = 112)
0.4 mg/kg
(n = 38)
0.8 mg/kg
(n = 35)
1.6 mg/kg
(n = 109)
0.4 mg/kg
(n = 38)
0.8 mg/kg
(n = 35)
1.6 mg/kg
(n = 109)
Total events 277 252 898 806 34 19 76 89
Nonfatal events 24 13 57 56
Patients with a fatal event 10 (26.3) 6 (17.1) 19 (17.4) 33 (29.5)
Patients with a nonfatal serious
adverse event
8 (21.0) 5 (14.3) 28 (25.7) 23 (20.5)
Patients with at least 1 event 35 (92.1) 31 (88.6) 103 (94.5) 111 (99.1) 18 (47.4) 11 (31.4) 47 (43.1) 56 (50.0)
Gastrointestinal disorders 17 (44.7) 16 (45.7) 63 (57.8) 49 (43.8) 3 (7.9) 2 (5.7) 11 (10.1) 6 (5.4)
Infections and infestations 16 (42.1) 16 (45.7) 60 (55.0) 47 (42.0) 5 (13.2) 5 (14.3) 18 (16.5) 18 (16.1)
Metabolism and nutrition
disorders
13 (34.2) 13 (37.1) 49 (45.0) 41 (36.6) 0 0 0 1 (0.9)
General disorders and
administration site conditions
10 (26.3) 13 (37.1) 44 (40.4) 43 (38.4) 2 (5.3) 0 5 (4.6) 9 (8.0)
Cardiac disorders 11 (28.9) 12 (34.3) 43 (39.4) 44 (39.3) 0 3 (8.6) 9 (8.3) 11 (9.8)
Psychiatric disorders 12 (31.6) 13 (37.1) 42 (38.5) 39 (34.8) 0 0 1 (0.9) 0
Respiratory, thoracic,
and mediastinal disorders
14 (36.8) 14 (40.0) 40 (36.7) 52 (46.4) 6 (15.8) 3 (8.6) 9 (8.3) 14 (12.5)
Vascular disorders 12 (31.6) 9 (25.7) 36 (33.0) 40 (35.7) 1 (2.6) 0 5 (4.6) 7 (6.3)
Investigations 8 (21.1) 10 (28.6) 30 (27.5) 30 (26.8) 0 0 1 (0.9) 1 (0.9)
Blood and lymphatic system
disorders
10 (26.3) 8 (22.9) 24 (22.0) 22 (19.6) 2 (5.3) 0 2 (1.8) 2 (1.8)
Skin and subcutaneous tissue
disorders
7 (18.4) 5 (14.3) 22 (20.2) 17 (15.2) 0 0 1 (0.9) 0
Nervous system disorders 6 (15.8) 10 (28.6) 19 (17.4) 15 (13.4) 4 (10.5) 1 (2.9) 4 (3.7) 1 (0.9)
Kidney and urinary disorders 6 (15.8) 2 (5.7) 16 (14.7) 12 (10.7) 1 (2.6) 0 1 (0.9) 2 (1.8)
Injury, poisoning,
and procedural complications
13 (34.2) 7 (20.0) 14 (12.8) 15 (13.4) 3 (7.9) 2 (5.7) 0 3 (2.7)
Musculoskeletal and connective
tissue disorders
3 (7.9) 1 (2.9) 13 (11.9) 14 (12.5) 0 0 0 1 (0.9)
Hepatobiliary disorders 1 (2.6) 1 (2.9) 9 (8.3) 9 (8.0) 1 (2.6) 0 0 4 (3.6)
Endocrine disorders 1 (2.6) 1 (2.9) 3 (2.8) 4 (3.6) 0 0 0 0
Eye disorders 3 (7.9) 1 (2.9) 3 (2.8) 2 (1.8) 0 0 0 0
Ear and labyrinth disorders 0 0 2 (1.8) 1 (0.9) 0 0 1 (0.9) 0
Neoplasm benign, malignant,
and unspecified
(including cyst and polyps)
0 0 1 (0.9) 1 (0.9) 0 0 0 0
Congenital, familial,
and genetic disorders
0 0 1 (0.9) 0 0 0 0 0
Reproductive system
and breast disorder
0 0 1 (0.9) 0 0 0 0 0
a Adverse events and serious adverse events were coded according to the
Medical Dictionary for Regulatory Activities, version 19.0. All patients who
died were analyzed and classified as a fatal serious adverse event. Patients
were counted once for each event category, even if they hadmultiple events
in that category. Only patients who received at least 1 dose of study drug were
included in the safety analysis data set.
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placebo group (odds ratio, 1.4 [95% CI, 0.8 to 2.4]; P = .28).
However, due to the null primary end point and the require-
ment for hierarchical testing, this finding does not represent
a formal analysis.
The exploratory end point, treatment effect of recombi-
nant alkaline phosphatase compared with placebo on ECC
improvement up to day 28, showed that the 1.6-mg/kg
recombinant alkaline phosphatase group exerted a differen-
tial treatment effect during the 28-day period (P = .04 for
interaction), driven by day 21 (mean difference, 16.3 mL/min
[95% CI, 3.07 to 29.5]; P = .02) and day 28 (mean differ-
ence, 18.5 mL/min [95% CI, 5.3 to 31.7]; P = .006) (Figure 2).
All-cause mortality at day 28 was lower in the 1.6-mg/kg
recombinant alkaline phosphatase group (n = 16 [14.4%]) vs
the placebo group (n = 31 [26.7%]; difference, 12.3% [95% CI,
1.9%-22.7%]; P = .02). This effect persisted to day 90, 17.1% in
the 1.6-mg/kg recombinant alkaline phosphatase group
(n = 19) vs 29.3% in the placebo group (n = 34) (difference,
12.2% [95% CI, 1.3% to 23.0%]; P = .03) (eFigure 24 in
Supplement 3). Kidney injury biomarkers, as well as other
nonkidney secondary end points, were not significantly
influenced by recombinant alkaline phosphatase treatment
(eTable 2 in Supplement 3). Per-protocol analyses yielded
comparable results. Data of other exploratory secondary end
points are provided in eTable 3 in Supplement 3.
Statistically significantdifferences in theeffectson thepri-
mary end point and key secondary end point were not ob-
served in the a priori defined exploratory subgroups (eFig-
ures 1-8 in Supplement 3).
Other End Points
Treatmentwithrecombinantalkalinephosphatasedidnotaffect
MAKEat28days,but resulted inasignificantly lower incidence
ofMAKEat60days (27.0% in the 1.6-mg/kg recombinant alka-
linephosphatase group [n = 30] vs 39.7% in theplacebogroup
[n = 46]; hazard ratio [HR], 1.8 [95% CI, 1.0 to 3.1]; P = .045)
and MAKE at 90 days (26.1% in the 1.6-mg/kg recombinant
alkaline phosphatase group: [n = 29] vs 39.7% in the placebo
group[n = 46];HR,1.9[95%CI, 1.1 to3.3];P = .03),mainlydriven
by a difference in survival (forMAKE definitions at eachmea-
surement,seeeTable2inSupplement3). Inflammatorybiomark-
ers, quality of life, and other exploratory end points were not
significantly influencedby recombinant alkalinephosphatase
treatment (eTables 2-3 and eFigures 9-23 in Supplement 3).
Adverse Events
In the safety data population (Table 2), 68 fatal SAEswere re-
portedduring the study. Fatal SAEswere reported in 26.3%of
the0.4-mg/kg recombinant alkalinephosphatasegroup, 17.1%
of the 0.8-mg/kg recombinant alkaline phosphatase group,
17.4% of the 1.6-mg/kg recombinant alkaline phosphatase
group,and29.5%in theplacebogroup.eTable4 inSupplement
3 provides a summary of cause of death by organ class and
Figure 3 illustrates the cumulative incidenceof fatal SAEsover
time for all treatment groups.Nonfatal SAEswere reported for
8patients (21.0%) in the0.4-mg/kg recombinantalkalinephos-
phatase group, 5 patients (14.3%) in the 0.8-mg/kg recombi-
nant alkaline phosphatase group, 28 patients (25.7%) in the
1.6-mg/kg recombinant alkaline phosphatase group, and 23
patients (20.5%) in theplacebogroup.Adverse eventswere re-
ported for the majority of patients in each of the groups
(0.4-mg/kg recombinant alkaline phosphatase group, 35
[92.1%]; 0.8-mg/kg recombinant alkaline phosphatase group,
31 [88.6%]; 1.6-mg/kgrecombinantalkalinephosphatasegroup,
103 [94.5%]; placebo, 111 [99.1%]),withmostAEs ineach treat-
ment group being either mild or moderate in severity. No re-
combinant alkaline phosphatase dose–dependency in the in-
cidenceandnatureof (S)AEswasobserved.Anti-drugantibody
titers were just above the detection limit in 9 patients treated
with recombinant alkaline phosphatase.
Post Hoc Analyses
Post hoc, MMRM sensitivity analysis, mixed-effects regres-
sion,withrandomtermsfor timeofmeasurementandsitewith-
out imputation, resulted in a mean difference of 27.6 mL/min
(95% CI, 8.7 to 46.6; P = .004) for day 21 and a mean differ-
ence of 18.2mL/min (95%CI, −2.5 to 38.9; P = .08) for day 28.
Baseline and day 1 ECC strongly correlated with AUC1-7 ECC
(r = 0.87; common slope, 1.01 [95% CI, 0.93–1.09]; P < .001).
Also, a lower baseline ECC correlated with a log-linear higher
relativeHR formortality according to aCoxmodel (eFigure 25
in Supplement 3). To test the robustness of the recombinant
alkaline phosphatase–mediated effect on survival, a forward
stepwise multivariable analysis was conducted. Of the vari-
ous covariates tested, recombinant alkaline phosphatase
treatment, baseline APACHE II score, baseline ECC, and time
to recombinant alkaline phosphatase treatment remained
Figure 3. Cumulative Incidence of Fatal Events FromBaseline to 90Days
for All Treatment Groups in the Safety Data Population of Patients
WhoWere Critically Ill With Sepsis-Associated Acute Kidney Infection
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Themedian observation time (95% CI) was 16.5 days (6-28) for the
0.4-mg/kg recombinant alkaline phosphatase group, 9.5 days (1-53) for
the 0.8-mg/kg recombinant alkaline phosphatase group, 9 days (5-21)
for the 1.6-mg/kg recombinant alkaline phosphatase group, and 8 days
(4-16) for the placebo group. All patients who died were analyzed and classified
as a fatal serious adverse event.
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significant additive prognostic factors included in the model
with a resulting treatment effect formortality (HR, 0.47 [95%
CI, 0.25 to 0.88]) was statistically significant with a 2-sided P
value of .02 (eTable 5 in Supplement 3).
Discussion
Among patientswith sepsis-associated AKI, human recombi-
nant alkalinephosphatase comparedwithplacebodidnot sig-
nificantly improve short-term kidney function. There are a
number of explanations for this finding, the first of which is
that this medication is not an effective treatment for sepsis-
associatedAKI.However, there are alternativepossible expla-
nations including, second, that creatinineand its clearanceare
recognized to be of limited precision to estimate kidney
function,26,27 especially during nonsteady state conditions;
however, a suitable clinical alternative is currently not avail-
able. Third, despite randomization, there was a slight imbal-
ance in kidney function between groups. Previouswork,28 as
well as the current trial, illustrate that thedegreeof initial kid-
ney dysfunction is prognostic for the extent of kidney recov-
ery and survival, asmore severe kidney failure correlateswith
worseoutcomes.Therefore, thesomewhat-more-impairedkid-
ney function in the recombinant alkaline phosphatase group
may account for the absence of a significantly more pro-
nounced improvement of ECC in the first week. Fourth, the
7-day timeframe was possibly too short, as differences in re-
covery of ECC between treatment groups emerged on day 21
and day 28. Fifth, the exploratory finding of lower mortality
in the recombinant alkaline phosphatase–treated group may
have had an influence on the primary outcome because poor
kidney function in the most severely ill—but surviving—
patients in the treatment group may have attenuated the in-
crease inECCof the recombinant alkalinephosphatase group.
In sepsis, injury is known to be heterogeneous through-
out the kidney with patchy tubular damage being the most
common histological finding.29 In contrast, ECC is a nonspe-
cific, late functionalmarker. Consequently, acutemeasures of
organ functionmaynot reflect underlying organ damage that
only becomes evident later. Therefore, an interventional
therapy that reduces damage and improves organ functionby
attenuating severity and duration of AKI, may prevent mal-
adaptive repair mechanisms and fibrosis, withmanifestation
of recoveryonlyafterweeks.30,31 Longer-termexploratorykid-
ney end points indicated that recombinant alkaline phospha-
tase resulted inmore complete long-term recovery of kidney
functioncomparedwithplacebo.Although thesebeneficial ef-
fects are more patient-centered and clinically relevant,32 it is
important toemphasize that thesewereexploratoryendpoints
of this study, so effects of recombinant alkaline phosphatase
on longer-term kidney function and survival should be inter-
preted as only hypothesis-generating.
In viewof thedetoxifyingproperties of alkaline phospha-
tase, therapeutic propertieswere investigated in animalmod-
els of sepsis, demonstrating improved outcomes.33 It re-
mains unclear to what extent kidney protection is mediated
through effects directly on tubular cells or through systemic
effects indirectlypreventingdamageto thekidneys,orwhether
kidney function improves aspart of a general effect of improv-
ing sepsis or a combination of the above. Alkaline phospha-
tase is depleted in the kidney following an ischemic insult,34
and recombinant alkalinephosphatase attenuates the inflam-
matory response in isolated human proximal tubule cells.35
However, systemic detoxifying properties may lead to more
swift normalization of circulating inflammatorymarkers11 in-
directlybenefiting thekidneys.As this latterobservationcould
not be confirmed in the current trial, the direct effects on kid-
ney tissue could be more important.
Adverse effectswere reported in themajority of patients,
independent of treatment with recombinant alkaline phos-
phatase or placebo. In accordance with the safety data from
the previously reported phase 1 studies,36 no compound-
specific or dose-related adverse effects emerged. Fatal SAEs
occurred in patients treatedwith recombinant alkaline phos-
phatase (17.4%) and placebo (29.5%).
Limitations
This study has several limitations. First, despite randomiza-
tion, a small but potentially relevant difference in baseline
ECC was present that may account for the lack of an effect on
the primary outcome measure. Second, the large number of
secondary end points may have introduced a type 1 error
related to the significant differences between groups, all of
which need to be interpreted as exploratory and hypothesis-
generating. Third, the exploratory analyses performed to
investigate the robustness of the observed mortality differ-
ence, were not preplanned and should be interpreted with
caution. Fourth, although no signals were observed in this
trial for AEs related to treatment, low incidence AEs may be
detected in larger trials only.
Conclusions
Among patients whowere critically ill with sepsis-associated
acute kidney injury, human recombinant alkaline phospha-
tase compared with placebo did not significantly improve
short-term kidney function. Further research is warranted to
assess other clinical outcomes.
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